Bar Ilan University, Ramat Gan, Israel.
ProPhase LLC, 3 Park Avenue, New York, NY 10016, USA; NYU School of Medicine, Dept. of Psychiatry, 1 Park Avenue, New York, NY 10016, USA.
Schizophr Res. 2021 Feb;228:529-533. doi: 10.1016/j.schres.2020.11.040. Epub 2020 Nov 25.
International Society for CNS Clinical Trials and Methodology convened an expert Working Group that assembled consistency/inconsistency flags for the Personal and Social Performance Scale (PSP). One hundred and forty seven flags were identified, 16 flag errors in deriving the PSP decile (i.e., total) score from the four individual domain scores, 74 flag inconsistencies between domain scores relative to Positive and Negative Symptom Scale (PANSS) item ratings and 57 flag inconsistencies between PSP decile score and PANSS items ratings. The flags were applied to assessments from randomized clinical trial data of antipsychotics in schizophrenia from almost 18,000 ratings. Twenty-two flags were raised in at least 5 of 1000 ratings. Nearly 20% of the PSP ratings had at least one inconsistency flag raised. Application of flags to clinical ratings may improve the reliability of ratings and validity of trials.
国际中枢神经系统临床试验和方法学学会召集了一个专家工作组,为个人和社会表现量表 (PSP) 制定了一致性/不一致性标记。共确定了 147 个标记,在从四个单独的领域分数推导出 PSP 十分位数(即总分)分数时出现了 16 个标记错误,在领域分数与阳性和阴性症状量表 (PANSS) 项目评分之间存在 74 个标记不一致,在 PSP 十分位数评分与 PANSS 项目评分之间存在 57 个标记不一致。这些标记应用于来自近 18000 项评分的精神分裂症抗精神病药物随机临床试验数据的评估中。有 22 个标记在至少 5/1000 项评分中被提出。近 20%的 PSP 评分至少有一个不一致标记被提出。标记在临床评分中的应用可能会提高评分的可靠性和试验的有效性。